Hoth Therapeutics Has Completed Its Analysis Of The Data From Its Phase 1B Clinical Trial Of Biolexa As A Therapeutic For Atopic Dermatitis; 78% Of Patients Reported That Their Overall Health Had Improved Since Starting Biolexa
Portfolio Pulse from Benzinga Newsdesk
Hoth Therapeutics has completed its analysis of the data from its Phase 1B clinical trial of Biolexa as a therapeutic for atopic dermatitis. The results show that 78% of patients reported that their overall health had improved since starting Biolexa.
September 06, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hoth Therapeutics' successful Phase 1B clinical trial of Biolexa could potentially boost its stock in the short term as it indicates progress in the company's product pipeline.
Positive clinical trial results often lead to increased investor confidence as they indicate progress in a company's product pipeline. This could potentially lead to an increase in Hoth Therapeutics' stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100